Trial Profile
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Axial spondyloarthritis; Spondylarthritis
- Focus Registrational; Therapeutic Use
- Acronyms ABILITY-1
- Sponsors Abbott GmbH & Co. KG; AbbVie
- 05 Apr 2017 Results of a post-hoc analysis assessing changes in objective inflammation over time in patients who had clinically active disease but a normal MRI (n=94), published in the Rheumatology
- 30 Oct 2013 Post-hoc analysis in patients with elevated C-reactive protein or MRI evidence of inflammation presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 30 Oct 2013 Post-hoc analysis of MRI-positive/C-reactive protein-positive patients over 104 weeks presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.